Literature DB >> 118941

Clinical pharmacokinetics of nitroxoline.

A Mrhar, Z Kopitar, F Kozjek, V Presl, R Karba.   

Abstract

14C-Nitroxoline was given orally to the rats, and its distribution as well as plasma and bile levels were determined autoradiographically and by the aid of radioactivity measurements, respectively. Nitroxoline was also given to the human volunteers orally and intravenously in three various doses and the corresponding urine concentrations of unconjugated and conjugated nitroxoline were determined spectrophotometrically. A pharmacokinetical model was generated on the basis of the results. The curve fitting procedure between total nitroxoline cumulative quantities in urine and the model response simulated on analog-hybrid computer enabled the evaluation of the validity of the chosen model as well as of the identification of its parameters.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 118941

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Biopharm        ISSN: 0340-0026


  9 in total

1.  Effect of nitroxoline on angiogenesis and growth of human bladder cancer.

Authors:  Joong Sup Shim; Yoshiyuki Matsui; Shridhar Bhat; Benjamin A Nacev; Jing Xu; Hyo-eun C Bhang; Surajit Dhara; Kee Chung Han; Curtis R Chong; Martin G Pomper; Alan So; Jun O Liu
Journal:  J Natl Cancer Inst       Date:  2010-11-18       Impact factor: 13.506

2.  In vitro Activity of Repurposed Nitroxoline Against Clinically Isolated Mycobacteria Including Multidrug-Resistant Mycobacterium tuberculosis.

Authors:  Ada Marie Hoffmann; Martina Wolke; Jan Rybniker; Georg Plum; Frieder Fuchs
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

3.  Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers.

Authors:  Florian M E Wagenlehner; Fabian Münch; Adrian Pilatz; Birte Bärmann; Wolfgang Weidner; Christine M Wagenlehner; Marion Straubinger; Holger Blenk; Wolfgang Pfister; Michael Kresken; Kurt G Naber
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

4.  Dihydroergosine pharmacokinetic modelling and simulation.

Authors:  R Karba; A Mrhar; F Kozjek; F Bremsak; Z Kopitar; A Lenardic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1983       Impact factor: 2.441

Review 5.  Review of the literature and individual patients' data meta-analysis on efficacy and tolerance of nitroxoline in the treatment of uncomplicated urinary tract infections.

Authors:  Kurt G Naber; Hiltrud Niggemann; Gisela Stein; Guenter Stein
Journal:  BMC Infect Dis       Date:  2014-11-27       Impact factor: 3.090

Review 6.  Recent advances in drug repositioning for the discovery of new anticancer drugs.

Authors:  Joong Sup Shim; Jun O Liu
Journal:  Int J Biol Sci       Date:  2014-06-10       Impact factor: 6.580

7.  Preclinical pharmacodynamic evaluation of antibiotic nitroxoline for anticancer drug repurposing.

Authors:  Q I Zhang; Shanshan Wang; Dexuan Yang; Kevin Pan; Linna Li; Shoujun Yuan
Journal:  Oncol Lett       Date:  2016-03-29       Impact factor: 2.967

8.  Functional Assessment of 2,177 U.S. and International Drugs Identifies the Quinoline Nitroxoline as a Potent Amoebicidal Agent against the Pathogen Balamuthia mandrillaris.

Authors:  Matthew T Laurie; Corin V White; Hanna Retallack; Wesley Wu; Matthew S Moser; Judy A Sakanari; Kenny Ang; Christopher Wilson; Michelle R Arkin; Joseph L DeRisi
Journal:  mBio       Date:  2018-10-30       Impact factor: 7.867

9.  Rationally repurposed nitroxoline inhibits preclinical models of Epstein-Barr virus-associated lymphoproliferation.

Authors:  Maite Ibáñez de Garayo; Wendi Liu; Nicole C Rondeau; Christopher B Damoci; J J L Miranda
Journal:  J Antibiot (Tokyo)       Date:  2021-06-23       Impact factor: 2.649

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.